1.605
price down icon5.03%   -0.085
after-market アフターアワーズ: 1.57 -0.035 -2.18%
loading
前日終値:
$1.69
開ける:
$1.54
24時間の取引高:
1.91M
Relative Volume:
1.01
時価総額:
$221.94M
収益:
-
当期純損益:
$-45.44M
株価収益率:
-4.5857
EPS:
-0.35
ネットキャッシュフロー:
$-42.28M
1週間 パフォーマンス:
-23.57%
1か月 パフォーマンス:
-41.21%
6か月 パフォーマンス:
-15.53%
1年 パフォーマンス:
-13.24%
1日の値動き範囲:
Value
$1.53
$1.695
1週間の範囲:
Value
$1.33
$2.435
52週間の値動き範囲:
Value
$0.765
$4.08

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name
名前
Compass Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
617-500-8099
Name
住所
80 GUEST STREET, BOSTON
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
CMPX's Discussions on Twitter

CMPX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CMPX
Compass Therapeutics Inc
1.605 221.94M 0 -45.44M -42.28M -0.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 66.76B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 開始されました Guggenheim Buy
2025-02-19 開始されました Piper Sandler Overweight
2024-12-23 開始されました D. Boral Capital Buy
2024-11-15 ダウングレード Leerink Partners Outperform → Market Perform
2024-09-16 アップグレード Ladenburg Thalmann Neutral → Buy
2023-01-31 開始されました Jefferies Buy
2023-01-27 開始されました Stifel Buy
2022-05-23 再開されました H.C. Wainwright Buy
2022-03-15 開始されました Ladenburg Thalmann Buy
2022-01-19 開始されました B. Riley Securities Buy
2021-12-22 開始されました Raymond James Outperform
2021-12-20 開始されました SVB Leerink Outperform
2021-12-15 開始されました Wedbush Outperform
すべてを表示

Compass Therapeutics Inc (CMPX) 最新ニュース

pulisher
Apr 02, 2025

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN

Apr 01, 2025
pulisher
Apr 01, 2025

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Compass Therapeutics to Host Webcast Highlighting Top-Line - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - The Manila Times

Mar 31, 2025
pulisher
Mar 30, 2025

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns - simplywall.st

Mar 30, 2025
pulisher
Mar 27, 2025

Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? - Yahoo

Mar 27, 2025
pulisher
Mar 25, 2025

Connor Clark & Lunn Investment Management Ltd. Trims Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World

Mar 25, 2025
pulisher
Mar 21, 2025

[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold

Mar 21, 2025
pulisher
Mar 21, 2025

10 Hot Biotech Stocks Under $5 - Insider Monkey

Mar 21, 2025
pulisher
Mar 18, 2025

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Canada Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Gallbladder Neoplasms Treatment Market Size in the 7MM - openPR

Mar 18, 2025
pulisher
Mar 13, 2025

Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 08, 2025

Rubicon Technology (NASDAQ:RBCN) Now Covered by Analysts at StockNews.com - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 28, 2025

D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics shares rise on pipeline progress - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics Reports 2024 Financial Results - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Compass Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat

Feb 26, 2025
pulisher
Feb 24, 2025

Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Compass stock gains amid Guggenheim buy rating - MSN

Feb 24, 2025

Compass Therapeutics Inc (CMPX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
大文字化:     |  ボリューム (24 時間):